Corporate Overview
 AndroScience Corporation (“ASC”) is a privately held San Diego, CA based biopharmaceutical company dedicated to the research, development, and commercialization of a proprietary series of small molecules which target androgen dependent diseases. The company’s platform of therapeutic candidates modulate androgen function via a completely novel mechanism of action by enhancing the degradation of the Androgen Receptor (AR), a class of transcription factor belonging to the steroid hormone nuclear receptor family. This new class of compounds, termed as Androgen Receptor Degradation Enhancers or ARD Enhancers, possess a number of therapeutic advantages over more conventional agents which inhibit AR activity by either blocking androgen binding to the AR or inhibiting the synthesis of androgen. Additionally, ASC’s ARD Enhancers are highly specific to the AR and do not lower levels of other nuclear receptors, do not possess partial agonist activity like certain conventional anti-androgens, and can be used in both systemic and topical based treatment formulations.
A diverse range of androgen dependent disease states and conditions exist today, representing considerable unmet medical need for which current treatment modalities under perform or possess untoward side effects. The therapeutic indications AndroScience is currently pursuing include Acne, Alopecia, and Wound Healing using topical based formulations and Prostate and other AR-related Cancers, Benign Prostatic Hyperplasia, and Kennedy’s Disease utilizing systemic based approaches. Since finalizing proof of concept work on ARD enhancers in 2004 and selecting ASC-J9® as its first lead candidate compound, ASC developmental achievements have included completing a Phase IIa clinical trial in acne in mid 2008, to initiate an IND approval for a Phase IIa trial in alopecia by mid 2009, and completion of formulation and final toxicology studies for both prostate cancer and Kennedy’s Disease by end of 2009.
For more information on each of AndroScience’s developmental programs please review our pipeline page for a description of each therapeutic indication and the advantages of an ARD Enhancer approach to disease management.
|